• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    12/27/23 4:07:01 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANGN alert in real time by email
    SC 13D/A 1 d287502dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Elicio Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    28657F103

    (CUSIP Number)

    Alejandro Moreno

    Langhorne S. Perrow

    c/o Access Industries, Inc.

    40 West 57th Street, 28th Floor

    New York, New York 10019

    (212) 247-6400

    with copies to:

    Nicholas P. Pellicani

    Debevoise & Plimpton LLP

    65 Gresham Street

    EC2V 7NQ

    London

    + 44 20 7786 9000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 22, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐

     

     

     


    CUSIP No. 28657F103

     

      1    

      NAME OF REPORTING PERSON.

     

      Access Industries Holdings LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      689,569 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      689,569 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      689,569 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      7.12%(1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO (Limited Liability Company)

     

    (1)

    All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on an aggregate of 8,407,106 shares of Common Stock issued and outstanding as of November 7, 2023, as set forth in the Issuer’s quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023 and 1,213,000 additional shares of Common Stock issued on December 22, 2023, as reported in the Issuer’s current report on Form 8-K, filed with the SEC on December 22, 2023.


    CUSIP No. 28657F103

     

      1    

      NAME OF REPORTING PERSON.

     

      Access Industries, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      689,569 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      689,569 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      689,569 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      7.12%(1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO (Limited Liability Company)

     

    (1)

    All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on an aggregate of 8,407,106 shares of Common Stock issued and outstanding as of November 7, 2023, as set forth in the Issuer’s quarterly report on Form 10-Q, filed with the SEC on November 13, 2023 and 1,213,000 additional shares of Common Stock issued on December 22, 2023, as reported in the Issuer’s current report on Form 8-K, filed with the SEC on December 22, 2023.


    CUSIP No. 28657F103

     

      1    

      NAME OF REPORTING PERSON.

     

      Access Industries Management, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      689,569 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      689,569 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      689,569 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      7.12%(1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO (Limited Liability Company)

     

    (1)

    All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on an aggregate of 8,407,106 shares of Common Stock issued and outstanding as of November 7, 2023, as set forth in the Issuer’s quarterly report on Form 10-Q, filed with the SEC on November 13, 2023 and 1,213,000 additional shares of Common Stock issued on December 22, 2023, as reported in the Issuer’s current report on Form 8-K, filed with the SEC on December 22, 2023.


    CUSIP No. 28657F103

     

      1    

      NAME OF REPORTING PERSON.

     

      Clal Industries Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Israel

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      689,569 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      689,569 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      689,569 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      7.12%(1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

    (1)

    All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on an aggregate of 8,407,106 shares of Common Stock issued and outstanding as of November 7, 2023, as set forth in the Issuer’s quarterly report on Form 10-Q, filed with the SEC on November 13, 2023 and 1,213,000 additional shares of Common Stock issued on December 22, 2023, as reported in the Issuer’s current report on Form 8-K, filed with the SEC on December 22, 2023.


    CUSIP No. 28657F103

     

      1    

      NAME OF REPORTING PERSON.

     

      Clal Biotechnology Industries Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Israel

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      689,569 shares

         8  

      SHARED VOTING POWER

     

      0 shares

         9  

      SOLE DISPOSITIVE POWER

     

      689,569 shares

       10  

      SHARED DISPOSITIVE POWER

     

      0 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      689,569 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      7.12%(1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

    (1)

    All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on an aggregate of 8,407,106 shares of Common Stock issued and outstanding as of November 7, 2023, as set forth in the Issuer’s quarterly report on Form 10-Q, filed with the SEC on November 13, 2023 and 1,213,000 additional shares of Common Stock issued on December 22, 2023, as reported in the Issuer’s current report on Form 8-K, filed with the SEC on December 22, 2023.


    CUSIP No. 28657F103

     

      1    

      NAME OF REPORTING PERSON.

     

      Len Blavatnik

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0 shares

         8  

      SHARED VOTING POWER

     

      689,569 shares

         9  

      SOLE DISPOSITIVE POWER

     

      0 shares

       10  

      SHARED DISPOSITIVE POWER

     

      689,569 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      689,569 shares

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

      7.12%(1)

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    (1)

    All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement are based on an aggregate of 8,407,106 shares of Common Stock issued and outstanding as of November 7, 2023, as set forth in the Issuer’s quarterly report on Form 10-Q, filed with the SEC on November 13, 2023 and 1,213,000 additional shares of Common Stock issued on December 22, 2023, as reported in the Issuer’s current report on Form 8-K, filed with the SEC on December 22, 2023.


    CONTINUATION PAGES TO SCHEDULE 13D

    This Amendment No. 2 to Schedule 13D is being filed by Access Industries Holdings LLC (“AIH”), Access Industries Management, LLC (“AIM”), Access Industries, LLC (“Access LLC”), Clal Industries Ltd. (“CI”), Clal Biotechnology Industries Ltd. (“CBI”) and Len Blavatnik (collectively, the “Reporting Persons”, and each, a “Reporting Person”) to report certain changes in beneficial ownership of common stock, $0.01 par value per share (the “Common Stock”) of Elicio Therapeutics, Inc. (the “Issuer”) held by the Reporting Persons. The agreement among the Reporting Persons relating to the joint filing of this Schedule 13D is attached as an exhibit hereto.

    The Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on June 12, 2023, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on August 30, 2023 (together, the “Schedule”), is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 2. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

     

    Item 5

    Interest in Securities of the Issuer

    Items 5(a) and (b) to the Schedule are hereby amended and restated as follows:

    (a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including but not limited to footnotes to such information) are incorporated herein by reference.

    The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Common Stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

    624,412 shares of Common Stock and 65,157 warrants to purchase shares of Common Stock at an exercise price of $60.77 are owned directly by CBI and each of AIH, Access LLC, AIM, CI and Mr. Blavatnik may be deemed to share voting and investment power over the securities owned by CBI because (i) Len Blavatnik controls AIM, AIH, Access LLC and AI International GP Limited (the general partner of AI SMS, as defined below), (ii) Access LLC controls a majority of the outstanding voting interests in AIH, (iii) AIM controls Access LLC and AIH, (iv) AIH owns a majority of the equity of AI SMS L.P. (“AI SMS”), (v) AI SMS owns a majority of the equity of AI Diversified Holdings Ltd. (“Holdings Limited”), (vi) Holdings Limited owns AI Diversified Parent S.à r.l., which owns AI Diversified Holdings S.à r.l., which owns Access AI Ltd (“Access AI”), (vii) Access AI wholly owns CI and (viii) CI is the controlling shareholder of CBI. Each of the Reporting Persons (other than CBI), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of the securities held directly by CBI.

     

    Item 7

    Materials to Be Filed as Exhibits

     

    Exhibit    Description
    99.6    Joint Filing Agreement, dated as of December 27, 2023.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: December 27, 2023

     

    ACCESS INDUSTRIES HOLDINGS LLC
       By: Access Industries Management, LLC, its Manager
       /s/ Alejandro Moreno
       Name: Alejandro Moreno
       Title: Executive Vice President
    ACCESS INDUSTRIES MANAGEMENT, LLC
       /s/ Alejandro Moreno
       Name: Alejandro Moreno
       Title: Executive Vice President
    ACCESS INDUSTRIES, LLC
       By: Access Industries Management, LLC, its Manager
       /s/ Alejandro Moreno
       Name: Alejandro Moreno
       Title: Executive Vice President
    CLAL INDUSTRIES LTD.    /s/ Nufar Malovani
       Name: Nufar Malovani
       Title: Deputy CEO and General Counsel
       /s/ Alon Heller
       Name: Alon Heller
       Title: Vice President
    CLAL BIOTECHNOLOGY INDUSTRIES LTD.    /s/ Liat Nissan
       Name: Liat Nissan
       Title: Vice President – Finance
       /s/ Assaf Segal
       Name: Assaf Segal
       Title: Chief Executive Officer
       *
       Name: Len Blavatnik

     

    *

    The undersigned, by signing his name hereto, executes this Amendment No. 2 to Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

     

    By:   /s/ Alejandro Moreno
      Name: Alejandro Moreno
      Attorney-in-Fact

     

    Get the next $ANGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGN

    DatePrice TargetRatingAnalyst
    12/10/2021$15.00 → $8.00Outperform
    Oppenheimer
    11/9/2021$100.00 → $50.00Buy
    HC Wainwright & Co.
    10/27/2021$40.00 → $15.00Buy
    Stifel
    More analyst ratings

    $ANGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split

    NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angion's common stock will begin trading on a split-adjusted basis when the market opens on June 2, 2023 under the new trading symbol "ELTX." As a result of the reverse stock split, the CUSIP number for Angion's common stock will now be 28657F103. The reverse stock split was previously approved by the stockholders of Ang

    6/1/23 8:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere

    1/17/23 5:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

    UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listin

    12/21/22 9:50:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer reiterated coverage on Angion Biomedica with a new price target

    Oppenheimer reiterated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $8.00 from $15.00 previously

    12/10/21 7:18:08 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Angion Biomedica with a new price target

    HC Wainwright & Co. reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $50.00 from $100.00 previously

    11/9/21 7:47:50 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel reiterated coverage on Angion Biomedica with a new price target

    Stifel reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $15.00 from $40.00 previously

    10/27/21 8:24:41 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ANGN
    SEC Filings

    View All

    $ANGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Demuth Peter

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:39 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haqq Christopher

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:41 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Piekos Brian

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:51 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    2/2/24 8:51:10 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    1/17/24 8:35:57 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    1/16/24 7:59:58 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chudnovsky Yekaterina bought $7,047,530 worth of shares (1,213,000 units at $5.81) (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    12/26/23 4:29:30 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Financials

    Live finance-specific insights

    View All

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere

    1/17/23 5:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

    -- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint. The GU

    12/9/21 4:05:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

    UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo (2.9 mL/min/1.73m2, p=0.33). In addition, ANG-3777 demonstrated an inconsistent benefit on key secondary endpoints. Based upon these

    10/26/21 4:05:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    12/27/23 4:07:01 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    12/26/23 4:25:31 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    8/30/23 5:16:05 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care